Trial Profile
A Retrospective Observational Research Study To Describe The Real World Use Of Bosutinib In The Uk And Netherlands
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Pfizer
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Status changed from active, no longer recruiting to completed,according to the results published at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 17 Aug 2016 Planned End Date changed from 31 Jul 2016 to 1 Oct 2016.